Evidence map›Paper›PMID 30809788›Full record

Trial reportPharmacoEconomics2019

Estimation of Cost for Endoscopic Screening for Esophageal Cancer in a High-Risk Population in Rural China: Results from a Population-Level Randomized Controlled Trial.

Fuxiao Li, Xiang Li, Chuanhai Guo, Ruiping Xu, Fenglei Li, Yaqi Pan, Mengfei Liu, Zhen Liu, Chao Shi, Hui Wang and 9 more

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in PharmacoEconomics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01688908 (Effcacy of Endoscopic Screening for Esophageal Cancer in China), which is not on this map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01688908 naactive not recruitingnot on this map

Effcacy of Endoscopic Screening for Esophageal Cancer in China (ESECC): a Population-based Randomized Controlled Trial

TypeinterventionalSponsorPeking UniversityRan2012 to 2027Enrolled33,948ConditionsEsophageal Squamous Cell Carcinoma, DysplasiaArmsEndoscopic Screening
3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 19 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Challenge and future of cancer screening in China: Insights from esophageal cancer screening practice.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2023
    Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Precision screening for esophageal squamous cell carcinoma in China.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2020
    Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 4 institutions in 1 country.

Fuxiao LiKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Laboratory of Genetics, Peking University Cancer Hospital and Institute, No. 52 Fucheng Rd, Beijing, 100142, People's Republic of China.
Xiang LiKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Laboratory of Genetics, Peking University Cancer Hospital and Institute, No. 52 Fucheng Rd, Beijing, 100142, People's Republic of China.
Chuanhai GuoKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Laboratory of Genetics, Peking University Cancer Hospital and Institute, No. 52 Fucheng Rd, Beijing, 100142, People's Republic of China.
Ruiping XuAnyang Cancer Hospital, Anyang, Henan Province, People's Republic of China.
Fenglei LiHua County People's Hospital, Anyang, Henan Province, People's Republic of China.
Yaqi PanKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Laboratory of Genetics, Peking University Cancer Hospital and Institute, No. 52 Fucheng Rd, Beijing, 100142, People's Republic of China.
Mengfei LiuKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Laboratory of Genetics, Peking University Cancer Hospital and Institute, No. 52 Fucheng Rd, Beijing, 100142, People's Republic of China.
Zhen LiuKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Laboratory of Genetics, Peking University Cancer Hospital and Institute, No. 52 Fucheng Rd, Beijing, 100142, People's Republic of China.
Chao ShiKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Laboratory of Genetics, Peking University Cancer Hospital and Institute, No. 52 Fucheng Rd, Beijing, 100142, People's Republic of China.
Hui WangKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Laboratory of Genetics, Peking University Cancer Hospital and Institute, No. 52 Fucheng Rd, Beijing, 100142, People's Republic of China.
Minmin WangKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Laboratory of Genetics, Peking University Cancer Hospital and Institute, No. 52 Fucheng Rd, Beijing, 100142, People's Republic of China.
Hongrui TianKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Laboratory of Genetics, Peking University Cancer Hospital and Institute, No. 52 Fucheng Rd, Beijing, 100142, People's Republic of China.
Fangfang LiuKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Laboratory of Genetics, Peking University Cancer Hospital and Institute, No. 52 Fucheng Rd, Beijing, 100142, People's Republic of China.
Ying LiuKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Laboratory of Genetics, Peking University Cancer Hospital and Institute, No. 52 Fucheng Rd, Beijing, 100142, People's Republic of China.
Jingjing LiKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Laboratory of Genetics, Peking University Cancer Hospital and Institute, No. 52 Fucheng Rd, Beijing, 100142, People's Republic of China.
Hong CaiKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Laboratory of Genetics, Peking University Cancer Hospital and Institute, No. 52 Fucheng Rd, Beijing, 100142, People's Republic of China.
Li YangSchool of Public Health, Peking University, Beijing, People's Republic of China.
Zhonghu HeKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Laboratory of Genetics, Peking University Cancer Hospital and Institute, No. 52 Fucheng Rd, Beijing, 100142, People's Republic of China. zhonghuhe@foxmail.com.
Yang KeKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Laboratory of Genetics, Peking University Cancer Hospital and Institute, No. 52 Fucheng Rd, Beijing, 100142, People's Republic of China. keyang@bjmu.edu.cn.
Peking University Cancer Hospital · CNPeking University · CNAnyang Tumor Hospital · CNThe Fifth People's Hospital of Anyang · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivePopulation-level endoscopic screening for esophageal cancer has been conducted in China for years. In this study, we aim to provide an updated and precise cost estimation for esophageal cancer screening based on a randomized controlled trial in a high-risk area in China.

methodsWe estimated the cost of esophageal cancer screening with chromoendoscopy using a micro-costing approach based on primary data of the ESECC (Endoscopic Screening for Esophageal Cancer in China) randomized controlled trial (NCT01688908) from a health sector perspective. Unit costs and quantities of resources were collected to obtain annual screening costs. The screening project was then theoretically expanded to a 10-year period to explore long-term trends of costs. Costs were adjusted to US dollars for the year 2018.

resultsIn the ESECC trial, screening cost per endoscopy with a valid pathologic diagnosis was $196, accounting for 3.82% of the gross domestic product per capita in Hua County, and the costs for detecting one esophageal cancer and one early-stage esophageal cancer were $26,347 and $37,687, respectively. In conventional screening in which protocol-driven costs were excluded, costs as above were $134, $18,074, and $25,853. The cost for detecting one gastric cardia cancer or stomach cancer was nine times higher than detecting one esophageal cancer owing to low prevalences of the two cancers. In a simulated 10-year screening project, annual cost decreased notably over time.

conclusionsDespite the relatively low absolute cost, population-level endoscopic screening will still be a heavy burden on local government considering the socioeconomic conditions. Long-lasting programs would be less costly and population-level screening would make little sense in non-high-risk regions.

Indexed as

Health Care CostsAgedEarly Detection of CancerEsophageal NeoplasmsEsophagoscopyHumansMiddle Aged

Identifiers

PMID30809788
OpenAlexW2917159352

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.